Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05130437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 9, 2021
Completion date
December 4, 2031
Enrollment
50 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

propionic acidemia